Who is sponsoring NCT04589754?

NCT04589754 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04589754?

Interventions in NCT04589754: Sintilimab plus chemotherapy, Adriamycin-based chemotherapy.

What condition does NCT04589754 study?

NCT04589754 studies Soft Tissue Sarcoma.

Is NCT04589754 still recruiting?

NCT04589754 is currently recruiting now. Last updated 2 January 2024.

Last reviewed 2024-01-02 · How we verify

NCT04589754

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adriamycin and Ifosfamide Combined With Sintilimab

Recruiting now Phase 2 Last updated 2 January 2024

What this trial tests

Phase 2 trial testing Sintilimab plus chemotherapy in Soft Tissue Sarcoma in 176 participants. Currently enrolling.

Timeline

26 July 2021

Primary endpoint
30 December 2025

30 July 2026

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	176
Start date	26 July 2021
Primary completion	30 December 2025
Estimated completion	30 July 2026
Sites	1 location across China

Drugs / interventions tested

Sintilimab plus chemotherapy — full drug profile →
Adriamycin-based chemotherapy — full drug profile →

Conditions studied

Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 14 to 70, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas.
Tian Z, Yao W. · · 2022 · cited 8× · PMID 36072581 · DOI 10.3389/fimmu.2022.898255

Verify or expand the search:

Other trials of Sintilimab plus chemotherapy

Trials testing the same drug.

NCT06267144 — Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer · unknown

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04589754 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 2 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04589754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing